High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study

Background As treatment for chronic hepatitis C (HCV) virus has evolved to all-oral, interferon-free directly acting antiviral (DAA) therapy, the impact of these improvements on patient adherence has not been described.